Yüklüyor......
Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody
The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, t...
Kaydedildi:
| Yayımlandı: | Mol Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5423175/ https://ncbi.nlm.nih.gov/pubmed/27103110 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2016.03.004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|